Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Conditions
Interventions
Mirikizumab
Locations
352
United States
Digestive Health Specialists
Dothan, Alabama, United States
Research Solutions of Arizona
Litchfield Park, Arizona, United States
Valleywise Health Medical Center
Phoenix, Arizona, United States
InSite Digestive Health Care
Arcadia, California, United States
Care Access - Berkeley
Berkeley, California, United States
Om Research LLC
Lancaster, California, United States
Start Date
July 18, 2018
Primary Completion Date
March 4, 2026
Completion Date
December 1, 2027
Last Updated
April 20, 2026
NCT07550673
NCT05739864
NCT04338204
NCT07271069
NCT06975722
NCT07185009
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions